Valbenazine

A novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor; is approved for the treatment of tardive dyskinesia.Other Indication Phase 3 Clinical (In Vitro) :Valbenazine exhibits VMAT2 binding affinity in rat striatum and human platelets with Kis of 110 and 150 nM, respectively. (In Vivo) :Valbenazine (10 mg/kg; orally) induces ptosis (primarily an adrenergic response) and increases plasma prolactin primarily a dopaminergic response.